162 related articles for article (PubMed ID: 35801173)
1. Inhibition of BET Protein Function Suppressed the Overactivation of the Canonical NF-κB Signaling Pathway in 6-OHDA-Lesioned Rat Model of Levodopa-Induced Dyskinesia.
Wan Y; Han L; Rong L; Yang S; Song L; Wu N; Liu Z; Gan J
Front Neurosci; 2022; 16():896322. PubMed ID: 35801173
[TBL] [Abstract][Full Text] [Related]
2. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease.
Wan Y; Wu N; Song L; Wang X; Liu Z; Yuan W; Gan J
Front Aging Neurosci; 2017; 9():331. PubMed ID: 29093677
[No Abstract] [Full Text] [Related]
3. Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway.
Yan A; Song L; Zhang Y; Wang X; Liu Z
Front Aging Neurosci; 2020; 12():625166. PubMed ID: 33597857
[No Abstract] [Full Text] [Related]
4. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
5. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of BET proteins in levodopa-induced dyskinesia.
A Figge D; Standaert DG
Neurobiol Dis; 2017 Jun; 102():125-132. PubMed ID: 28286180
[TBL] [Abstract][Full Text] [Related]
7. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
Chotibut T; Fields V; Salvatore MF
Mol Pharmacol; 2014 Dec; 86(6):675-85. PubMed ID: 25208966
[TBL] [Abstract][Full Text] [Related]
8. Histological Correlates of Neuroanatomical Changes in a Rat Model of Levodopa-Induced Dyskinesia Based on Voxel-Based Morphometry.
Zhang X; Chen W; Wu Y; Zeng W; Yuan Y; Cheng C; Yang X; Wang J; Yang X; Xu Y; Lei H; Cao X; Xu Y
Front Aging Neurosci; 2021; 13():759934. PubMed ID: 34776935
[TBL] [Abstract][Full Text] [Related]
9. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Padovan-Neto FE; Cavalcanti-Kiwiatkoviski R; Carolino RO; Anselmo-Franci J; Del Bel E
Neuropharmacology; 2015 Feb; 89():87-99. PubMed ID: 25196732
[TBL] [Abstract][Full Text] [Related]
10. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
[TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Pinna A; Costa G; Serra M; Contu L; Morelli M
Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
[TBL] [Abstract][Full Text] [Related]
12. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
13. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Xie CL; Wang WW; Zhang SF; Yuan ML; Che JY; Gan J; Song L; Yuan WE; Liu ZG
Sci Rep; 2014 Dec; 4():7506. PubMed ID: 25511986
[TBL] [Abstract][Full Text] [Related]
14. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
[TBL] [Abstract][Full Text] [Related]
15. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
16. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
[TBL] [Abstract][Full Text] [Related]
17. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
[TBL] [Abstract][Full Text] [Related]
18. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
19. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
Bortolanza M; Cavalcanti-Kiwiatkoski R; Padovan-Neto FE; da-Silva CA; Mitkovski M; Raisman-Vozari R; Del-Bel E
Neurobiol Dis; 2015 Jan; 73():377-87. PubMed ID: 25447229
[TBL] [Abstract][Full Text] [Related]
20. Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.
Del-Bel E; Padovan-Neto FE; Szawka RE; da-Silva CA; Raisman-Vozari R; Anselmo-Franci J; Romano-Dutra AC; Guimaraes FS
Neurotox Res; 2014 Jan; 25(1):33-44. PubMed ID: 23807548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
